Peter Michael Bruno, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Naphthyridines | 1 | 2020 | 118 | 0.730 |
Why?
|
Benzothiazoles | 1 | 2020 | 252 | 0.700 |
Why?
|
Organoplatinum Compounds | 2 | 2017 | 429 | 0.680 |
Why?
|
Coordination Complexes | 4 | 2017 | 80 | 0.530 |
Why?
|
Antineoplastic Agents | 13 | 2020 | 13626 | 0.510 |
Why?
|
Cisplatin | 2 | 2017 | 1654 | 0.500 |
Why?
|
Carboplatin | 1 | 2017 | 802 | 0.490 |
Why?
|
Ribosomes | 1 | 2017 | 502 | 0.490 |
Why?
|
Phenanthrolines | 3 | 2017 | 52 | 0.430 |
Why?
|
Neoplastic Stem Cells | 5 | 2017 | 1373 | 0.410 |
Why?
|
Cell Survival | 2 | 2020 | 6035 | 0.380 |
Why?
|
Osmium | 2 | 2014 | 20 | 0.260 |
Why?
|
Copper | 2 | 2016 | 380 | 0.240 |
Why?
|
Organometallic Compounds | 2 | 2016 | 660 | 0.220 |
Why?
|
Doxorubicin | 2 | 2020 | 2217 | 0.210 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2017 | 3633 | 0.200 |
Why?
|
Lymphoma | 2 | 2020 | 1881 | 0.190 |
Why?
|
Cell Line, Tumor | 9 | 2020 | 16736 | 0.190 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2020 | 116 | 0.180 |
Why?
|
Thiocarbamates | 1 | 2017 | 32 | 0.160 |
Why?
|
Phenanthridines | 1 | 2017 | 59 | 0.160 |
Why?
|
Nanoparticles | 3 | 2017 | 1900 | 0.160 |
Why?
|
Nickel | 1 | 2017 | 131 | 0.150 |
Why?
|
Platinum Compounds | 1 | 2017 | 104 | 0.150 |
Why?
|
RNA Interference | 4 | 2020 | 2985 | 0.150 |
Why?
|
Cobalt | 1 | 2016 | 161 | 0.150 |
Why?
|
Naproxen | 1 | 2016 | 100 | 0.150 |
Why?
|
Principal Component Analysis | 2 | 2017 | 966 | 0.140 |
Why?
|
Sphingolipids | 1 | 2017 | 168 | 0.140 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 258 | 0.140 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 2280 | 0.140 |
Why?
|
Rhenium | 1 | 2015 | 15 | 0.140 |
Why?
|
Nitrogen Compounds | 1 | 2014 | 6 | 0.140 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 109 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2020 | 1255 | 0.130 |
Why?
|
2,2'-Dipyridyl | 1 | 2013 | 11 | 0.130 |
Why?
|
DNA Damage | 4 | 2017 | 2434 | 0.130 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 333 | 0.130 |
Why?
|
Aneuploidy | 1 | 2017 | 479 | 0.130 |
Why?
|
Camptothecin | 1 | 2016 | 551 | 0.120 |
Why?
|
Genetic Techniques | 1 | 2016 | 435 | 0.120 |
Why?
|
Endonucleases | 1 | 2016 | 388 | 0.120 |
Why?
|
Apoptosis | 4 | 2017 | 9973 | 0.110 |
Why?
|
Drug Synergism | 2 | 2017 | 1854 | 0.110 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 657 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 11201 | 0.110 |
Why?
|
Embryo, Mammalian | 1 | 2017 | 1749 | 0.100 |
Why?
|
Immunoconjugates | 1 | 2017 | 830 | 0.100 |
Why?
|
Neoplasms | 2 | 2017 | 20528 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8571 | 0.100 |
Why?
|
Molecular Conformation | 3 | 2016 | 550 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4751 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2016 | 2947 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2017 | 1426 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4893 | 0.090 |
Why?
|
Blotting, Western | 1 | 2017 | 5379 | 0.090 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2016 | 752 | 0.080 |
Why?
|
Drug Combinations | 1 | 2012 | 1928 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3574 | 0.080 |
Why?
|
Drug Design | 1 | 2012 | 1099 | 0.080 |
Why?
|
Fibroblasts | 1 | 2017 | 4233 | 0.070 |
Why?
|
Homeostasis | 1 | 2017 | 3332 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 5198 | 0.070 |
Why?
|
Structure-Activity Relationship | 3 | 2016 | 3206 | 0.070 |
Why?
|
Breast Neoplasms | 3 | 2016 | 20062 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14902 | 0.060 |
Why?
|
Cyclooxygenase 2 | 2 | 2016 | 630 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2016 | 3948 | 0.060 |
Why?
|
Necrosis | 2 | 2017 | 1645 | 0.050 |
Why?
|
Mice | 6 | 2017 | 80375 | 0.050 |
Why?
|
Mice, Nude | 2 | 2017 | 3801 | 0.050 |
Why?
|
Immunotherapy | 1 | 2015 | 4095 | 0.050 |
Why?
|
Reactive Oxygen Species | 2 | 2017 | 2099 | 0.040 |
Why?
|
Sphingosine N-Acyltransferase | 1 | 2017 | 8 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6592 | 0.040 |
Why?
|
Glucosyltransferases | 1 | 2017 | 106 | 0.040 |
Why?
|
Animals | 7 | 2017 | 169420 | 0.040 |
Why?
|
Genetic Variation | 1 | 2012 | 6664 | 0.040 |
Why?
|
Ceramides | 1 | 2017 | 197 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9504 | 0.040 |
Why?
|
Cyclooxygenase 1 | 1 | 2016 | 111 | 0.040 |
Why?
|
Humans | 14 | 2020 | 715777 | 0.040 |
Why?
|
Cell Proliferation | 3 | 2017 | 10620 | 0.040 |
Why?
|
Models, Biological | 1 | 2013 | 9809 | 0.040 |
Why?
|
DNA Modification Methylases | 1 | 2016 | 208 | 0.030 |
Why?
|
Polyesters | 1 | 2016 | 368 | 0.030 |
Why?
|
Drug Stability | 1 | 2015 | 304 | 0.030 |
Why?
|
Prodrugs | 1 | 2016 | 273 | 0.030 |
Why?
|
Receptor, PAR-1 | 1 | 2015 | 114 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 356 | 0.030 |
Why?
|
Morpholines | 1 | 2017 | 572 | 0.030 |
Why?
|
Dacarbazine | 1 | 2016 | 588 | 0.030 |
Why?
|
Drug Carriers | 1 | 2016 | 686 | 0.030 |
Why?
|
Molecular Structure | 1 | 2016 | 1950 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2016 | 1177 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1323 | 0.020 |
Why?
|
Systems Biology | 1 | 2012 | 491 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2017 | 6641 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2016 | 2016 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 1842 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2993 | 0.020 |
Why?
|
Ligands | 1 | 2013 | 3294 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2758 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2883 | 0.020 |
Why?
|
Carcinoma | 1 | 2016 | 2321 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2016 | 2210 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 5467 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10499 | 0.020 |
Why?
|
Cell Line | 1 | 2016 | 16576 | 0.010 |
Why?
|
Female | 5 | 2017 | 377204 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19910 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22665 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 13758 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2017 | 62004 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23729 | 0.010 |
Why?
|
Male | 1 | 2017 | 350324 | 0.000 |
Why?
|